Stockreport

Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF Collaboration to evaluate the full-potential of NKTR-214 plus Opdivo (nivolumab) across numerous tumors, based on promising early data from o [Read more]